Industry & Policy News

[Nature] On 19 January, the UK Health and Security Agency, the public-health authority, declared a national incident over rising cases of measles. The agency has logged more than 200 cases since 1 October 2023.

[Longeveron Inc] Longeveron Inc. announced it received a notice of patent allowance from the United States Patent and Trademark Office for Medicinal Signaling Cells, the technology behind its lead investigational product Lomecel-BTM. The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as COVID and the flu.

[Fierce Biotech] Sanofi is paying $40 million to add another cytokine—IL-10—to its hit list. This has secured Sanofi the chance to work with Synthekine to overcome long-standing barriers to the use of the cytokine in the treatment of inflammatory diseases.

[BioCardia^®, Inc.] BioCardia®, Inc. announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction.

[FibroGen, Inc.] FibroGen, Inc. announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's Precision PromiseSM Phase II/III adaptive platform trial, which evaluated pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with mPDAC.

[ScienceInsider] Researchers report that open-access papers have a greater reach than paywalled ones in two key ways: They attract more total citations, and those citations come from scholars in a wider range of locations, institutions, and fields of research.